Key Points
- Amir Heshmatpour, President of Neonc Technologies, bought 10,000 shares on May 1 at an average price of $4.16 for $41,600, increasing his holdings to 3,072,000 shares (a 0.33% uptick) as disclosed in an SEC filing.
- Shares opened at $4.14 (12‑month range $3.20–$12.99) and analysts are mixed—BTIG initiated a Buy with a $15 target while Weiss rates it a Sell and Zacks a Hold—leaving a consensus rating of "Hold" and an average price target of $15.
- Neonc is a clinical‑stage biotech focused on CNS therapies, with lead programs including NEO100 (Phase 2a for glioblastoma) and NEO212 (preclinical).
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour bought 10,000 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $4.16 per share, for a total transaction of $41,600.00. Following the transaction, the president owned 3,072,000 shares of the company's stock, valued at $12,779,520. The trade was a 0.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Neonc Technologies Trading Up 2.0%
Shares of Neonc Technologies stock opened at $4.14 on Tuesday. Neonc Technologies Holdings, Inc. has a 12-month low of $3.20 and a 12-month high of $12.99. The business's 50 day moving average is $7.20 and its 200-day moving average is $8.44.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on NTHI shares. BTIG Research initiated coverage on shares of Neonc Technologies in a report on Friday, April 24th. They set a "buy" rating and a $15.00 target price on the stock. Zacks Research upgraded shares of Neonc Technologies to a "hold" rating in a research note on Wednesday, January 14th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Neonc Technologies in a research note on Friday, March 27th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $15.00.
Get Our Latest Report on NTHI
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its holdings in Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company's stock valued at $76,000 after buying an additional 8,982 shares during the last quarter. Foundations Investment Advisors LLC bought a new position in Neonc Technologies in the 3rd quarter valued at approximately $100,000. SLT Holdings LLC bought a new position in Neonc Technologies in the 3rd quarter valued at approximately $100,000. Goldman Sachs Group Inc. bought a new position in Neonc Technologies in the 4th quarter valued at approximately $124,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Neonc Technologies in the 4th quarter valued at approximately $126,000.
Neonc Technologies Company Profile
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
